SUBSCRIBE
SUBSCRIBE

Latigo Biotherapeutics, Inc.

NEWS
Pictured: Falling Pain Pill Bottles / Taylor Tiede
Latigo Launches into Non-Opioid Pain Medicine Space with $135 Million Series A
Two weeks after Vertex’s Phase III data for VX-548 reenergized the field, Latigo Biotherapeutics announced $135 million in Series A funds to push its own NaV1.8 inhibitor into Phase II.
February 13, 2024
 · 
3 min read
 · 
Heather McKenzie
JOBS
IN THE PRESS
Press Releases
Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair
November 19, 2024
 · 
3 min read
Press Releases
Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical Trial of LTG-305 for Non-Opioid Treatment of Pain
October 17, 2024
 · 
3 min read
Press Releases
Latigo Biotherapeutics Appoints Tim Lugo as Chief Financial Officer and Adds Beth Seidenberg and Jim Tananbaum to Board of Directors
September 9, 2024
 · 
6 min read
Press Releases
Latigo Biotherapeutics Announces Positive Phase 1 Data for Lead Non-Opioid Pain Medicine Candidate and Appoints Neil Singla, M.D., Chief Medical Officer
August 19, 2024
 · 
5 min read
Press Releases
Latigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer, Positioning Company for Rapid Growth
July 22, 2024
 · 
3 min read
Biotech Beach
Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines
February 14, 2024
 · 
3 min read